

Robert F Schwabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9369905/publications.pdf>

Version: 2024-02-01

75
papers

14,040
citations

71102

41
h-index

82547

72
g-index

79
all docs

79
docs citations

79
times ranked

21519
citing authors

#	ARTICLE	IF	CITATIONS
1	TLR4 enhances TGF- β 2 signaling and hepatic fibrosis. <i>Nature Medicine</i> , 2007, 13, 1324-1332.	30.7	1,712
2	Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. <i>Nature</i> , 2015, 527, 472-476.	27.8	1,498
3	The microbiome and cancer. <i>Nature Reviews Cancer</i> , 2013, 13, 800-812.	28.4	1,338
4	Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. <i>Nature Communications</i> , 2013, 4, 2823.	12.8	1,012
5	Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance. <i>Gastroenterology</i> , 2014, 147, 765-783.e4.	1.3	587
6	Gremlin 1 Identifies a Skeletal Stem Cell with Bone, Cartilage, and Reticular Stromal Potential. <i>Cell</i> , 2015, 160, 269-284.	28.9	535
7	Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. <i>Hepatology</i> , 2013, 58, 1461-1473.	7.3	468
8	Deactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice. <i>Gastroenterology</i> , 2012, 143, 1073-1083.e22.	1.3	422
9	The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 153-186.	22.4	422
10	A molecular single-cell lung atlas of lethal COVID-19. <i>Nature</i> , 2021, 595, 114-119.	27.8	411
11	The gut microbiome and liver cancer: mechanisms and clinical translation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 527-539.	17.8	401
12	High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. <i>Nature Protocols</i> , 2015, 10, 305-315.	12.0	400
13	Toll-Like Receptor Signaling in the Liver. <i>Gastroenterology</i> , 2006, 130, 1886-1900.	1.3	377
14	Apoptosis and necroptosis in the liver: a matter of life and death. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 738-752.	17.8	364
15	Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2020, 158, 1913-1928.	1.3	346
16	The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. <i>Journal of Clinical Investigation</i> , 2015, 125, 539-550.	8.2	307
17	Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2016, 24, 848-862.	16.2	279
18	Gut microbiome in HCC – Mechanisms, diagnosis and therapy. <i>Journal of Hepatology</i> , 2020, 72, 230-238.	3.7	206

#	ARTICLE	IF	CITATIONS
19	Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis. <i>Cell Stem Cell</i> , 2016, 18, 797-808.	11.1	181
20	Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. <i>Journal of Clinical Investigation</i> , 2015, 125, 3891-3903.	8.2	175
21	Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. <i>Cancer Cell</i> , 2021, 39, 866-882.e11.	16.8	159
22	Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	151
23	Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	144
24	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020, 31, 406-421.e7.	16.2	141
25	CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. <i>Gut</i> , 2014, 63, 1782-1792.	12.1	118
26	Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020, 31, 969-986.e7.	16.2	117
27	In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis. <i>Cell Stem Cell</i> , 2016, 18, 809-816.	11.1	109
28	Hepatocellular Carcinomas Originate Predominantly from Hepatocytes and Benign Lesions from Hepatic Progenitor Cells. <i>Cell Reports</i> , 2017, 19, 584-600.	6.4	102
29	NLR Family Pyrin Domain-Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice. <i>Hepatology</i> , 2019, 69, 845-859.	7.3	100
30	Negative regulation of NF- κ B p65 activity by serine 536 phosphorylation. <i>Science Signaling</i> , 2016, 9, ra85.	3.6	96
31	Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	91
32	High-Mobility Group Box 1 Is Dispensable for Autophagy, Mitochondrial Quality Control, and Organ Function In Vivo. <i>Cell Metabolism</i> , 2014, 19, 539-547.	16.2	82
33	IKK β phosphorylates p65 at S468 in transactivation domain 2. <i>FASEB Journal</i> , 2005, 19, 1758-1760.	0.5	79
34	HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. <i>Journal of Clinical Investigation</i> , 2018, 128, 2436-2451.	8.2	78
35	Origin and Function of Myofibroblasts in the Liver. <i>Seminars in Liver Disease</i> , 2015, 35, 097-106.	3.6	72
36	Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. <i>Gastroenterology</i> , 2019, 157, 793-806.e14.	1.3	67

#	ARTICLE	IF	CITATIONS
37	MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. <i>Hepatology</i> , 2018, 67, 2414-2429.	7.3	64
38	Maladaptive regeneration – the reawakening of developmental pathways in NASH and fibrosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 131-142.	17.8	64
39	Epithelial Transforming Growth Factor- β^2 Signaling Does Not Contribute to Liver Fibrosis but Protects Mice From Cholangiocarcinoma. <i>Gastroenterology</i> , 2016, 150, 720-733.	1.3	57
40	Serum Amyloid A Induces Inflammation, Proliferation and Cell Death in Activated Hepatic Stellate Cells. <i>PLoS ONE</i> , 2016, 11, e0150893.	2.5	52
41	SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 341-364.	4.5	45
42	Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. <i>Journal of Hepatology</i> , 2021, 75, 888-899.	3.7	45
43	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. <i>Gut</i> , 2023, 72, 736-748.	12.1	42
44	Understanding the cellular interactome of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2022, 4, 100524.	4.9	35
45	Targeting Liver Cancer: First Steps toward a miRacle?. <i>Cancer Cell</i> , 2011, 20, 698-699.	16.8	34
46	Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. <i>Journal of Hepatology</i> , 2021, 74, 613-626.	3.7	34
47	Contributions of Fibroblasts, Extracellular Matrix, Stiffness, and Mechanosensing to Hepatocarcinogenesis. <i>Seminars in Liver Disease</i> , 2019, 39, 315-333.	3.6	33
48	Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. <i>Gut</i> , 2016, 65, 1721-1732.	12.1	31
49	Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis. <i>Journal of Hepatology</i> , 2022, 77, 15-28.	3.7	31
50	Bacteria Deliver a Genotoxic Hit. <i>Science</i> , 2012, 338, 52-53.	12.6	28
51	TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver. <i>PLoS ONE</i> , 2016, 11, e0158819.	2.5	28
52	Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. <i>Cancer Research</i> , 2021, 81, 5336-5352.	0.9	27
53	TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2022, 76, 910-920.	3.7	27
54	The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver. <i>Science Translational Medicine</i> , 2022, 14, eabe5795.	12.4	25

#	ARTICLE	IF	CITATIONS
55	Mouse Models of Liver Fibrosis. <i>Methods in Molecular Biology</i> , 2021, 2299, 339-356.	0.9	23
56	Contribution of Underlying Connective Tissue Cells to Taste Buds in Mouse Tongue and Soft Palate. <i>PLoS ONE</i> , 2016, 11, e0146475.	2.5	21
57	Effect of rifaximin on infections, acute and chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH). <i>Liver International</i> , 2022, 42, 1109-1120.	3.9	20
58	Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 850-861.	3.7	17
59	c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis. <i>Nature Metabolism</i> , 2020, 2, 1350-1367.	11.9	16
60	β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma. <i>Gastroenterology</i> , 2022, 163, 481-494.	1.3	13
61	FoxM1 Induces CCL2 Secretion From Hepatocytes Triggering Hepatic Inflammation, Injury, Fibrosis, and Liver Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 555-556.	4.5	8
62	HMGB1 and injury amplification. <i>Oncotarget</i> , 2015, 6, 23048-23049.	1.8	8
63	Gut microbiota and Toll-like receptors set the stage for cytokine-mediated failure of antibacterial responses in the fibrotic liver. <i>Gut</i> , 2017, 66, 396-398.	12.1	7
64	Nuclear HMGB1 protects from nonalcoholic fatty liver disease through negative regulation of liver X receptor. <i>Science Advances</i> , 2022, 8, eabg9055.	10.3	7
65	NAD + Supplementation as a Novel Approach to curing HCC?. <i>Cancer Cell</i> , 2014, 26, 777-778.	16.8	5
66	Soluble Fibers Improve Metabolic Syndrome but May Cause Liver Disease and Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 739-741.	7.3	3
67	Chimeric Antigen Receptor T Cells as Senolytic and Antifibrotic Therapy. <i>Hepatology</i> , 2021, 73, 1227-1229.	7.3	3
68	Leukocyte-Derived High-Mobility Group Box 1 Governs Hepatic Immune Responses to <i>Listeria monocytogenes</i> . <i>Hepatology Communications</i> , 2021, 5, 2104-2120.	4.3	3
69	Animal models of HCC – “When injury meets mutation”. <i>Journal of Hepatology</i> , 2018, 68, 193-194.	3.7	2
70	A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 765-767.	3.7	2
71	Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 36-44.	0.5	2
72	Embracing basic and clinical innovation in hepatology. <i>JHEP Reports</i> , 2019, 1, 343-344.	4.9	0

#	ARTICLE	IF	CITATIONS
73	Regenerating research and life. JHEP Reports, 2020, 2, 100172.	4.9	0
74	Assessing the roles of various retinoidâ€metabolizing CYP enzymes in liver disease. FASEB Journal, 2009, 23, 215.2.	0.5	0
75	Breakthroughs in hepatology. Journal of Hepatology, 2022, 76, 1247-1248.	3.7	0